Cargando…

Development of Hip Bone Geometry in Transgender Adolescents Resembles the Experienced Gender if GnRHa Treatment Is Started in Early, but Not Late, Puberty

Bone geometry can be described in terms of periosteal and endocortical growth and is partly determined by sex steroids. Periosteal and endocortical apposition are thought to be regulated by testosterone and estrogen, respectively. Gender-affirming hormone (GAH) treatment with sex steroids in transge...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Loos, Maria A T C, Hellinga, Ilse, Vlot, Mariska C, Klink, Daniel T, Den Heijer, Martin, Wiepjes, Chantal M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Reproductive Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265905/ http://dx.doi.org/10.1210/jendso/bvab048.1606

Ejemplares similares

Development of Hip Bone Geometry During Gender‐Affirming Hormone Therapy in Transgender Adolescents Resembles That of the Experienced Gender When Pubertal Suspension Is Started in Early Puberty
por: van der Loos, Maria ATC, et al.
Publicado: (2021)

Just as Tall on Testosterone; a Neutral to Positive Effect on Adult Height of GnRHa and Testosterone in Trans Boys
por: Willemsen, Lieve Anne, et al.
Publicado: (2022)

A single sample GnRHa stimulation test in the diagnosis of precocious puberty
por: Yazdani, Parvin, et al.
Publicado: (2012)

Treatment of central precocious puberty using low dose GnRH analogs (GnRHa)
por: Jahagirdar, Rahul, et al.
Publicado: (2015)

Fertility preservation and GnRHa for chemotherapy: debate
por: Blumenfeld, Zeev
Publicado: (2014)

GnRHa trigger—the story of the ugly duckling
por: Humaidan, Peter, et al.
Publicado: (2023)

Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty
por: Lewis, Katherine A, et al.
Publicado: (2009)

GnRHa/Stanozolol Combined Therapy Maintains Normal Bone Growth in Central Precocious Puberty
por: Zhu, Shunye, et al.
Publicado: (2021)

The Efficacy of GnRHa Alone or in Combination with rhGH for the Treatment of Chinese Children with Central Precocious Puberty
por: Wang, Mengjie, et al.
Publicado: (2016)

The Luteal Phase after GnRHa Trigger-Understanding An Enigma
por: Leth-Moller, Kathrine, et al.
Publicado: (2014)

Transgender Girls Grow Tall: Adult Height Is Unaffected by GnRH Analogue and Estradiol Treatment
por: Boogers, Lidewij Sophia, et al.
Publicado: (2022)

Treatment of Endometriosis with the GnRHa Deslorelin and Add-Back Estradiol and Supplementary Testosterone
por: Agarwal, Sanjay K., et al.
Publicado: (2015)

Response of South Indian girls with central precocious puberty to gonadotrophin analogue (GnRHa) therapy – a single center experience
por: Selvaraj, Meghana, et al.
Publicado: (2021)

Growth, bone maturation and ovarian size in girls with early and fast puberty (EFP) and effects of three years treatment with GnRH analogue (GnRHa)
por: Alaaraj, Nada, et al.
Publicado: (2021)

Comparison of Clinical Efficacy between a Single Administration of Long-Acting Gonadotrophin-Releasing Hormone Agonist (GnRHa) and Daily Administrations of Short-Acting GnRHa in In Vitro Fertilization-Embryo Transfer Cycles
por: Cheon, Kang Woo, et al.
Publicado: (2008)

Perspectives on the co-treatment with GnRHa in female patients undergoing hematopoietic stem cell transplantation
por: Cima, Luminita Nicoleta, et al.
Publicado: (2017)

Curative GnRHa treatment has an unexpected repressive effect on Sertoli cell specific genes
por: Gegenschatz-Schmid, Katharina, et al.
Publicado: (2018)

Empty Follicle Syndrome Following GnRHa Trigger in PCOS Patients Undergoing IVF Cycles
por: Deepika, Krishna, et al.
Publicado: (2018)

GnRHa Before Single-Port Laparoscopic Hysterectomy in a Large Barrel-Shaped Uterus
por: Torng, Pao-Ling, et al.
Publicado: (2019)

Testicular expression of long non–coding RNAs is affected by curative GnRHa treatment of cryptorchidism
por: Hadziselimovic, Faruk, et al.
Publicado: (2019)

Transdermal versus oral estrogen: clinical outcomes in patients undergoing frozen-thawed single blastocyst transfer cycles without GnRHa suppression, a prospective randomized clinical trial
por: Kahraman, Semra, et al.
Publicado: (2018)

GnRHa protects the ovarian reserve by reducing endoplasmic reticulum stress during cyclophosphamide-based chemotherapy
por: Li, Xiaolin, et al.
Publicado: (2021)

GnRHa for Ovarian Protection and the Association between AMH and Ovarian Function during Adjuvant Chemotherapy for Breast Cancer
por: Zhong, Ying, et al.
Publicado: (2019)

Expression profiles of E/P receptors and fibrosis in GnRHa-treated and -untreated women with different uterine leiomyomas
por: Khan, Khaleque N., et al.
Publicado: (2020)

GnRHa as a treatment for letrozole-resistant recurrent adult granulosa cell tumors: A case report
por: Zhuang, Yuan, et al.
Publicado: (2021)

Effect of recombinant LH supplementation timing on clinical pregnancy outcome in long-acting GnRHa downregulated cycles
por: Huang, Chenyang, et al.
Publicado: (2022)

Pituitary suppression with a GnRHa short protocol in an alternate day schedule associated with rhCG microdoses
por: Rodrigues, Rosane S., et al.
Publicado: (2014)

Gonadotropin releasing hormone analogue (GnRHa) alters the expression and activation of Smad in human endometrial epithelial and stromal cells
por: Luo, Xiaoping, et al.
Publicado: (2003)

Effects of GnRHa treatment during vitellogenesis on the reproductive physiology of thermally challenged female Atlantic salmon (Salmo salar)
por: Anderson, Kelli, et al.
Publicado: (2017)

Pre-treatment with GnRHa or ulipristal acetate prior to laparoscopic and laparotomic myomectomy: A systematic review and meta-analysis
por: de Milliano, Inge, et al.
Publicado: (2017)

Central Precocious Puberty and Response to GnRHa Therapy in Children with Cerebral Palsy and Moderate to Severe Motor Impairment: Data from a Longitudinal, Case-Control, Multicentre, Italian Study
por: Bruzzi, Patrizia, et al.
Publicado: (2017)

Long-term effects and significant adverse drug reactions (ADRs) associated with the use of gonadotropin-releasing hormone analogs (GnRHa) for central precocious puberty: a brief review of literature
por: De Sanctis, Vincenzo, et al.
Publicado: (2019)

Retraction Note to: Gonadotropin releasing hormone analogue (GnRHa) alters the expression and activation of Smad in human endometrial epithelial and stromal cells
por: Luo, Xiaoping, et al.
Publicado: (2015)

Comparison Between PPOS and GnRHa-Long Protocol in Clinical Outcome with the First IVF/ICSI Cycle: A Randomized Clinical Trial
por: Xi, Qianwen, et al.
Publicado: (2020)

OR15-01 Blockers and Bones: Loss of Absolute Bone Mineral Density Is Common in Trans- and Gender- Diverse Adolescents Treated with GnRHa
por: Ferguson, Grant, et al.
Publicado: (2020)

Benefits from the first year of GnRHa therapy in boys with idiopathic central precocious puberty when initiating treatment after age 9 years: findings from a real-world retrospective study
por: Ni, Ming-ming, et al.
Publicado: (2022)

STROBE-GnRHa pretreatment in frozen-embryo transfer cycles improves clinical outcomes for patients with persistent thin endometrium: A case-control study
por: Liu, Yixuan, et al.
Publicado: (2022)

MTHFR 677TT is associated with decreased number of embryos and cumulative live birth rate in patients undergoing GnRHa short protocol: a retrospective study
por: Zeng, Hong, et al.
Publicado: (2022)

Safety and efficacy concerns of long-acting GnRHa trigger for ovulation induction in oncological patients undergoing oocyte cryopreservation: a call for caution and further investigation
por: Ingold, C., et al.
Publicado: (2023)

HCG Trigger of GnRH Agonist-Induced Functional Ovarian Cysts Does Not Decrease Clinical Pregnancy Rate in GnRHa Pretreated Frozen Cycles: Evidence From a Retrospective Cohort Study
por: Zeng, Hong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tni4m6ktv5i37ctll7vuh51hoq